Alpha Cognition Earnings Call Transcripts
Fiscal Year 2025
-
ZUNVEYL adoption accelerated in Q4 2025, with strong sales growth, expanding prescriber base, and improved payer access. The company remains well-funded, expects continued growth in 2026, and is advancing key clinical studies to further differentiate its product.
-
The discussion highlighted ZUNVEYL's commercial progress in the long-term care Alzheimer's market, with expanding payer coverage, robust clinical trial plans, and new formulations targeting unmet needs. Key catalysts include inflection in sales by mid-2026, international approvals, and pivotal trial data.
-
Q3 2025 saw robust ZUNVEYL sales growth, expanded long-term care engagement, and improved financials, with a strengthened balance sheet and reduced expense guidance. Market access and prescriber adoption accelerated, supported by new studies and strategic pricing actions.
-
ZUNVEYL, a newly FDA-approved Alzheimer's drug, launched in April 2024 with a focus on the U.S. long-term care market, showing strong early adoption and superior tolerability. The company targets profitability by 2027, is expanding its pipeline, and anticipates significant market share growth.
-
Q2 2025 marked the first earnings post-ZUNVEYL launch, with $1.7M in revenue and strong early adoption in long-term care. Operating loss rose to $5.7M, but liquidity remains solid at $39.4M. Market access expanded, and ex-U.S. growth is on track for late 2026.
-
First quarter marked by ZUNVEYL's commercial launch, strong early adoption in long-term care, and improved financials with reduced losses and a debt-free balance sheet. Positive market feedback, minimal payer restrictions, and robust liquidity support continued growth.
-
ZUNVEYL is set for a March launch in the $2B long-term care Alzheimer's market, offering improved tolerability and efficacy over current treatments. The commercial team is nearly fully staffed, pricing is set at $749/month, and the company targets break-even in three years.
Fiscal Year 2024
-
Reported strong liquidity after a $52M capital raise and NASDAQ cross-listing, with ZUNVEYL's U.S. launch showing positive early demand and prescriber feedback. 2024 net loss increased to $14.6M, but cash is expected to support break-even by year three if sales and expense targets are met.